Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting

New England Journal of Medicine

Volumn 374, Issue 14, 2016, Pages 1356-1367

  Navari, Rudolph M ^a,b   Aapro, Matti ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harper Cancer Institute   (United States)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DRONABINOL; FLUOROURACIL; FOSAPREPITANT; GABAPENTIN; GRANISETRON; HALOPERIDOL; METOCLOPRAMIDE; NABILONE; NETUPITANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; ROLAPITANT; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SUBSTANCE P; UNINDEXED DRUG;

ASTHENIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL RESEARCH; CONSTIPATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE PERSONNEL; HICCUP; HUMAN; MEDICAL EDUCATION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QT PROLONGATION; REVIEW; SOMNOLENCE; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; DRUG COMBINATION; NAUSEA; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NAUSEA; NEUROKININ-1 RECEPTOR ANTAGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84963819050     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1515442     Document Type: Review

References (77)

1. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 2014; 722: 26-37.
2. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of anti-emetics. Br Med J 1979; 1: 1323-4.
3. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics. Cancer 2004; 100: 2261-8.
4. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent anti-emetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012; 23: 1986-92.
5. Affronti ML, Schneider SM, Herndon JE II, Schlundt S, Friedman HS. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 2014; 22: 1897-905.
6. Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 2016; 34: 381-6.
7. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 2011; 19: 843-51.
8. Viale PH, Grande C, Moore S. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2012(4); 16: E133-41.
9. American Society of Clinical Oncology. ASCO 50th anniversary poll names the top 5 advances from the past 50 years. September 17, 2014 (http://www.asco.org/press-center/asco-50th-anniversary-poll-names-top-5-advances-past-50-years).
10. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9.
11. NCCN Clinical Practice Guidelines in Oncology. Antiemesis, version 2. Fort Washington, PA: Harborside Press, 2015.
12. Morrow GR, Hickok JT, Burish TG, Rosenthal SN. Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 1996; 19: 199-203.
13. Navari RM Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015; 2015: 595894.
14. Morrow GR, Roscoe JA, Hynes HE, Flynn PJ, Pierce HI, Burish T. Progress in reducing anticipatory nausea and vomiting: a study of community practice. Support Care Cancer 1998; 6: 46-50.
15. Hesketh PJ Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-94.
16. Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 2013; 14: 757-66.
17. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
18. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-8.
19. MASCC antiemetic guidelines. Hillerød, Denmark: Multinational Association of Supportive Care in Cancer, 2013 (http://www.mascc.org/antiemetic-guidelines).
20. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
21. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990; 113: 834-40.
22. Warr D, Willan A, Fine S, et al. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1991; 83: 1169-73.
23. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
24. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of highdose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
25. Hesketh P, Navari RM, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous on-dansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242-9.
26. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-8.
27. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, singledose trial versus dolasetron. Cancer 2003; 98: 2473-82.
28. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7.
29. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340-6.
30. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015; 16: 1079-89.
31. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 1071-8.
32. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-33.
33. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25: 1333-9.
34. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-53.
35. Gralla RJ Metoclopramide: a review of antiemetic trials. Drugs 1983; 25: Suppl 1: 63-73.
36. Frytak S, Moertel CG, Eagan RT, O'Fallon JR. A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy. Proc Am Soc Clin Oncol 1981; 22: 421.
37. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905-9.
38. Gralla RJ, Tyson LB, Clark RA, Bordin LA, Kelsen DP, Kalman LB. Antiemetic trials with high dose metoclopramide: Superiority over THC, and preservation of efficacy in subsequent chemotherapy courses. Proc Am Soc Clin Oncol 1982; 1: 58.
39. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 1981; 7: 11-4.
40. Roila F, Tonato M, Ballatori E, Del Favero A. Prevention of cisplatin-induced emesis. Lancet 1992; 340: 972.
41. Joss RA, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Ann Oncol 1994; 5: 253-8.
42. Navari RM, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-8.
43. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10.
44. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007; 15: 1023-33.
45. NCCN antiemesis practice guidelines. Oncology (Williston Park) 1997; 11(11A): 57-89.
46. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998; 9: 811-9.
47. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
48. European Society for Medical Oncology. ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2001; 12: 1059-60.
49. Navari RM Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - two new agents. J Support Oncol 2003; 1: 89-103.
50. Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107: 469-78.
51. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-24.
52. Aapro M, Fabi A, Nolè F, et al. Doubleblind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010; 21: 1083-8.
53. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol - EASE. J Clin Oncol 2011; 29: 1495-501.
54. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015; 26: 1081-90.
55. Navari RM Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 2015; 9: 155-61.
56. Varubi (rolapitant) prescribing information. Waltham, MA: Tesaro, 2015 (http://varubirx.com/downloads/VARUBI-(rolapitant)-Full-Prescribing-Information-September-2015.pdf).
57. Navari RM Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2014; 722: 180-6.
58. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188-95.
59. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21: 1655-63.
60. Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al. Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer 2012; 20: 601-6.
61. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemo-therapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-43.
62. Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 2008; 4: 99-107.
63. Molassiotis A, Aapro M, Dicato M, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014; 47(5): 839-848.e4.
64. Kris MG, Urba SG, Schwartzberg LS. Clinical roundtable monograph: treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clin Adv Hematol Oncol 2011; 9: Suppl: 1-15.
65. Dranitsaris G, Bouganim N, Milano C, et al. Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Support Oncol 2013; 11: 14-21.
66. Bayo J, Fonseca PJ, Hernando S, et al. Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles. Clin Transl Oncol 2012; 14: 413-22.
67. Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 2014; 22: 469-77.
68. Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 2012; 20: 141-7.
69. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014; 722: 197-202.
70. Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33: 910-5.
71. Vidall C, Dielenseger P, Farrell C, et al. Evidence-based management of chemotherapy-induced nausea and vomiting: a position statement from a European cancer nursing forum. Ecancermedical-science 2011; 5: 211.
72. Roila F. Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 2004; 12: 446-53.
73. Iihara H, Ishihara M, Matsuura K, et al. Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic. J Eval Clin Pract 2012; 18: 753-60.
74. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 2001; 9: 611-8.
75. Navari RM Treatment of chemotherapy-induced nausea. Community Oncol 2012; 9: 20-6.
76. Foubert J, Vaessen G. Nausea: the neglected symptom? Eur J Oncol Nurs 2005; 9: 21-32.
77. Jordan K, Jahn F, Jahn P, Feyer P, Müller-Tidow C, Hesketh P. Proposed emetic risk classification of 32 recently approved anticancer agents. Presented at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer, Copenhagen, April 14-17, 1985 (po ster).